City Therapeutics, Inc. (CTY) Stock Price & Analysis
City Therapeutics, Inc. (CTY) closed at USD 20.77 on Thursday, October 22, 2026, up 1.66% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 20.43; the Oct 22, 2026 session ranged USD 19.75–20.85 on volume of 127,596 shares. Market capitalization is $1.05B, with a 52-week range of USD 19.75–23.88 (NGM). Source: Nexqual, retrieved October 23, 2026 at 10:30 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CTY.md
Key facts (CTY)
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $6.1M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: None.
- Total return with dividends: 1Y -7.3% vs S&P 500 +14.9%; 5Y -7.3% vs S&P 500 +80.3%.
Insider purchases (SEC Form 4, open-market, last ~7 months) (CTY)
2 purchases, $6.1M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-10-19 | Arch Venture Partners Xii, Llc | 170,000 | $3.1M | 18 | Too little history (no open-market trades in 2023–2025) | |
| 2026-10-19 | Nelsen Robert | Director | 170,000 | $3.1M | 18 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (CTY)
Consensus None.
Total return (dividends reinvested) (CTY)
| 1Y (from 2026-10-16) | 5Y (from 2026-10-12) | |
|---|---|---|
| Total return | -7.3% | -7.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | — | — |
| Volatility (annualized) | 40.4% | 38.5% |
| Max drawdown | -8.8% (Oct 2026→Oct 2026) | -7.3% (Oct 2026→Oct 2026) |
Companies that name CTY in their SEC reports
| Relationship to CTY | Company | Filing | Sentence |
|---|---|---|---|
| partner | BIOGEN INC. (BIIB) | 10-K Feb 6, 2026 | “For additional information on our strategic research arrangement with City Therapeutics, please read Note 19, Collaborative and Other Relationships, to our consolidated financial statements included in this report.” |
CTY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 23, 2026 at 10:30 UTC)
| Price | USD 20.77 |
|---|---|
| Change | ▲ 1.66% (up) |
| Previous Close | USD 20.43 |
| Open | USD 20.41 |
| Day Range | USD 19.75 – 20.85 |
| 52-Week Range | USD 19.75 – 23.88 |
| Volume | 127,596 shares |
| Market Cap | $1.05B |
| Exchange | NGM |
Analyst Ratings (CTY)
Wall Street analysts rate CTY "None", per Nexqual as of October 23, 2026 at 10:30 UTC.
| Consensus Rating | None |
|---|
Earnings (CTY)
Source: Nexqual, October 23, 2026 at 10:30 UTC.
Financials & Fundamentals (CTY)
| Total Revenue | $14.34M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +14.00% |
| Gross Margin | +0.00% |
| Operating Margin | -804.20% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.46 |
| Current Ratio | 2.71 |
| Total Cash | $169.60M |
| Total Debt | $57.04M |
Source: Nexqual, October 23, 2026 at 10:30 UTC.
Financial Health Score (CTY)
Nexqual rates City Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:30 UTC.
| Growth | Solid — Revenue +14% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $170M cash vs $57M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$78M (TTM) |
| Efficiency | Mixed — No data |
Ownership (CTY)
| Insider Ownership | +7.37% |
|---|---|
| Institutional Ownership | +5.09% |
| Shares Outstanding | 50.33M |
| Float | 3.07M |
Source: Nexqual, October 23, 2026 at 10:30 UTC.
Leadership (CTY)
City Therapeutics, Inc. is led by Andrew C. Orth, President, CEO & Director, per Nexqual as of October 23, 2026 at 10:30 UTC.
| President, CEO & Director | Andrew C. Orth |
|---|---|
| Chief Scientific Officer | Tracy Zimmermann |
| Chief Financial Officer | Keith C. Regnante |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:30 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt